File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Scopus: eid_2-s2.0-0033104631
- PMID: 10069538
- WOS: WOS:000078832400004
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: The in vitro post-antifungal effect of nystatin on Candida species of oral origin
Title | The in vitro post-antifungal effect of nystatin on Candida species of oral origin |
---|---|
Authors | |
Keywords | Candida Nystatin Post-antifungal effect |
Issue Date | 1999 |
Publisher | Blackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JOPM |
Citation | Journal Of Oral Pathology And Medicine, 1999, v. 28 n. 3, p. 112-116 How to Cite? |
Abstract | The post-antifungal effect (PAFE) is defined as the suppression of growth that persists following limited exposure of yeasts to antimycotics and subsequent removal of the drug. Although limited data are available on the PAFE of nystatin on oral isolates of C. albicans, there is no information on non-albicans Candida species. As nystatin is the commonest antifungal agent prescribed in dentistry, the main aim of this investigation was to measure the PAFE of oral isolates of Candida belonging to six different species (five isolates each of C. albicans, C. tropicalis, C. krusei, C. parapsilosis, C. glabrata and C. guilliermondii) following limited exposure (1 h) to nystatin. The yeasts were examined for the presence of the PAFE after 1 h exposure to the minimum inhibitory concentration (MIC) of nystatin. The PAFE was determined as the difference in time (h) required for the growth of the drug-free control and the drug-exposed test cultures to increase to the 0.05 absorbance level following removal of the antifungal agent. The mean duration of nystatin-elicited PAFE was lowest for C. albicans (6.85 h) and greatest for C. parapsilosis (15.17 h), while C. krusei (11.58 h), C. tropicalis (12.73 h), C. glabrata (8.51 h), and C. guilliermondii (8.68 h) elicited intermediate values. These findings clarify another intriguing possibility for the persistent, chronic recurrence of oral C. albicans infections despite apparently adequate antifungal drug regimens. The significant variations in nystatin-induced PAFE amongst non-albicans species may also have clinical implications, in terms of nystatin regimens used in the management of these fungal infections. |
Persistent Identifier | http://hdl.handle.net/10722/154060 |
ISSN | 2023 Impact Factor: 2.7 2023 SCImago Journal Rankings: 0.716 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ellepola, ANB | en_US |
dc.contributor.author | Samaranayake, LP | en_US |
dc.date.accessioned | 2012-08-08T08:23:04Z | - |
dc.date.available | 2012-08-08T08:23:04Z | - |
dc.date.issued | 1999 | en_US |
dc.identifier.citation | Journal Of Oral Pathology And Medicine, 1999, v. 28 n. 3, p. 112-116 | en_US |
dc.identifier.issn | 0904-2512 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/154060 | - |
dc.description.abstract | The post-antifungal effect (PAFE) is defined as the suppression of growth that persists following limited exposure of yeasts to antimycotics and subsequent removal of the drug. Although limited data are available on the PAFE of nystatin on oral isolates of C. albicans, there is no information on non-albicans Candida species. As nystatin is the commonest antifungal agent prescribed in dentistry, the main aim of this investigation was to measure the PAFE of oral isolates of Candida belonging to six different species (five isolates each of C. albicans, C. tropicalis, C. krusei, C. parapsilosis, C. glabrata and C. guilliermondii) following limited exposure (1 h) to nystatin. The yeasts were examined for the presence of the PAFE after 1 h exposure to the minimum inhibitory concentration (MIC) of nystatin. The PAFE was determined as the difference in time (h) required for the growth of the drug-free control and the drug-exposed test cultures to increase to the 0.05 absorbance level following removal of the antifungal agent. The mean duration of nystatin-elicited PAFE was lowest for C. albicans (6.85 h) and greatest for C. parapsilosis (15.17 h), while C. krusei (11.58 h), C. tropicalis (12.73 h), C. glabrata (8.51 h), and C. guilliermondii (8.68 h) elicited intermediate values. These findings clarify another intriguing possibility for the persistent, chronic recurrence of oral C. albicans infections despite apparently adequate antifungal drug regimens. The significant variations in nystatin-induced PAFE amongst non-albicans species may also have clinical implications, in terms of nystatin regimens used in the management of these fungal infections. | en_US |
dc.language | eng | en_US |
dc.publisher | Blackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JOPM | en_US |
dc.relation.ispartof | Journal of Oral Pathology and Medicine | en_US |
dc.subject | Candida | - |
dc.subject | Nystatin | - |
dc.subject | Post-antifungal effect | - |
dc.subject.mesh | Analysis Of Variance | en_US |
dc.subject.mesh | Antifungal Agents - Pharmacology - Therapeutic Use | en_US |
dc.subject.mesh | Candida - Drug Effects - Growth & Development | en_US |
dc.subject.mesh | Candidiasis, Oral - Drug Therapy - Microbiology | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Microbial Sensitivity Tests | en_US |
dc.subject.mesh | Nystatin - Pharmacology - Therapeutic Use | en_US |
dc.subject.mesh | Recurrence | en_US |
dc.subject.mesh | Statistics, Nonparametric | en_US |
dc.title | The in vitro post-antifungal effect of nystatin on Candida species of oral origin | en_US |
dc.type | Article | en_US |
dc.identifier.email | Samaranayake, LP:lakshman@hku.hk | en_US |
dc.identifier.authority | Samaranayake, LP=rp00023 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.pmid | 10069538 | - |
dc.identifier.scopus | eid_2-s2.0-0033104631 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0033104631&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 28 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.spage | 112 | en_US |
dc.identifier.epage | 116 | en_US |
dc.identifier.isi | WOS:000078832400004 | - |
dc.publisher.place | Denmark | en_US |
dc.identifier.scopusauthorid | Ellepola, ANB=6604060863 | en_US |
dc.identifier.scopusauthorid | Samaranayake, LP=7102761002 | en_US |
dc.identifier.issnl | 0904-2512 | - |